Stoke Therapeutics (STOK) Non-Current Assets (2018 - 2026)

Stoke Therapeutics' Non-Current Assets history runs 9 years deep, the most recent figure standing at $76.6 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 145.88% year-over-year to $76.6 million; the TTM figure through Mar 2026 stood at $391.7 million (up 225.27% YoY), while the FY2025 annual figure was $112.7 million, up 190.56% from the prior year.
• Non-Current Assets was $76.6 million for Q1 2026 at Stoke Therapeutics, down from $112.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $114.5 million in Q2 2025 to a low of $9.9 million in Q3 2023.
• Historically, Non-Current Assets has averaged $36.3 million across 5 years, with a median of $13.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets fell 24.22% in 2023, then soared 964.18% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $12.0 million in 2022, then grew by 8.39% to $13.0 million in 2023, then surged by 198.38% to $38.8 million in 2024, then soared by 190.56% to $112.7 million in 2025, then plunged by 32.06% to $76.6 million in 2026.
• The last three Non-Current Assets figures came in at $76.6 million (Q1 2026), $112.7 million (Q4 2025), and $87.8 million (Q3 2025), per Business Quant data.